TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients with GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oxidative stress markers (serum ox-LDL and GSH-Px)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Number of Hospitalizations or Deaths Prior to Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Incidence of Severe Infusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of Treatment-related Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of Treatment-related Acute Respiratory Distress Syndrome (ARDS)
Endpoint domain: Adverse events/effects
Primary endpoint: combined rate of major adverse events (MACE) at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in General Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Social Development
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Fruit and Vegetable Intake (Skin Carotenoids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in clinical outcomes of Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success in clinical outcomes of Dyslipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in clinical outcomes of primary disease Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aesthetic Appearance Improvement Likert Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Dimple Depth Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area under the plasma concentration time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum observed concentration of the analyte in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time of maximum concentration of the analyte in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-TOMEKA® usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rejection Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Justice Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pain and discomfort level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Leg muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain-related Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with mRS ≤ 2
Endpoint domain: Mortality/survival
Primary endpoint: Variation in the Visual Analogic Scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in immunization coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in timeliness of immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute change from baseline of chloride secretory ion current response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of the risk of smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes towards smoking and tobacco control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for additional IV medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Automatic Postural Response (APR) Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of malaria diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of malaria diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of self-reported clinical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of Pain Catastrophizing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patterns of Positive Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patterns of Negative Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiopulmonary Exercise Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative maximum NT-proBNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pediatric Crohn's Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of JNJ-55308942
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-55308942
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in plasma concentrations of pharmacologically active constituents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of motor and non-motor symptoms of PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Daily Average Pain Intensity NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the overall SymptoMScreen score in participants with RMS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in the overall SymptoMScreen score in participants with PPMS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in reading ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Freedom of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Continued intended performance of the HighLife™ bioprosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 1-Year Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: CA 15-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pressure of arterial oxygen (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Transient Dyspnea Index (TDI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unexpected Toxicities During First 2 Cycles of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Number of units transfused per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tattoo Clearance Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of neurogenic stunned myocardium (NSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-t of Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMT Peds Scale Part 1: Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMT Peds Score Part 2: Foot and Ankle Involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CMT Peds Scale Part 8: Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State of immune tolerance to graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean cumulative irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total duration for investigational product preparation and administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Isokinetic knee muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change From Baseline in Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and feasibility of renal denervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Anxiety Symptoms Scale (PASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time until surgical retreatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge of the physician concerning Diane-35
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Pain Intensity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average crying and fussing times
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS for stability of monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self reported depression measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MMR (Measles, Mumps, Rubella) vaccination coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of SGI-110
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of angiographic in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circuit lifetime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of scarring and volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(TAU) of Asunaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reasoning ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of recovery scores (QoR 40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thrombocytaggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: objective measures of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: sleep related ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: daytime respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: feasibility of concurrent IMRT combined with capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in INTEM parameters from preoperative to postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EXTEM parameters from preoperative to postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FIBTEM parameters from preoperative to postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Death or re-hospitalization due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence rate of lower grade sarcoma
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Aprepitant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD Symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in structural integrity of the rotator cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma concentrations of pravastatin and raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMAX (Maximum Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitigation of multi-organ dysfunction (MODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Subjects Seizure Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With A Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRI T2*/R2* for liver and heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peroneal motor nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum levels of IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal temperature measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma-concentration time curve to last measured time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral bioavailability based on the ratio of AUC after oral dosing to the AUC after i.v. dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Co-oximetry Measure of Arterial Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' Perceived Self-efficacy to Communicate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients Active Participatory Communication Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Susceptibility genes for chronic lymphocytic leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HBV immunization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Dorsiflexion of Injured Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in fibromyalgia symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HAM-D-29 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores of global development Quotient (WISC-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peak Percent Change From Baseline in Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability according to emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Six minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shuttle walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Body Weight From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Any Adverse Events, Serious Adverse Events and Death
Endpoint domain: Adverse events/effects
Primary endpoint: Saliva melatonin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour 6-SMT urine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA < 200 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to scheduled clinic attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Medication adherence self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Papilla Fill Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crestal Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI resting state correlates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Repeatability of conjunctivochalasis measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow extension range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of caregivers administering zinc
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of caregivers reporting zinc administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of resistant hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Audiometric Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight bearing without aid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of signs for complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in attitudes toward obese individuals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neck Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who would choose outside of center administration of mifepristone again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who would recommend outside-of-center administration to a friend
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Medication Changes and Lifestyle Modifications Recommended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Times High μCor Measurements Were Reduced Below Threshold Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid femoral pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Displacement of blood volume of the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported functional outcome- American Shoulder and Elbow Surgeons Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-reported functional outcome- Single Assessment Numeric Evaluation score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Therapeutic Success of Spiolto® Respimat® Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HMB Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adaptive functional improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Use of IV fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes